VaxGen IPO Could Allow For Completion of AIDS Vaccine Phase III Trials
VaxGen plans to meet the 2002 deadline for an AIDS vaccine NDA submission set by marketing partner Genentech with the help of an initial public offering of 3.1 mil. shares.
You may also be interested in...
VaxGen is pushing back its BLA filing for the AIDS vaccine AIDSVAX until 2004 while it works to fulfill pre-approval manufacturing requirements
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011